Enliven Therapeutics, Inc.
ELVN
NASDAQ
Healthcare
$49.82
+2.17%gain today
Market position
Market cap rank
#1661
of 2,614
1-day
+2.17%
1-month
+40.26%
6-month
+223.51%
YTD
+220.59%
1-year
+141.38%
5-year
+64.10%
Key figures
Market cap
$3.56B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-8.4
FY 2025
EPS
-$1.83
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$774.13M
FY 2025
EV / EBITDA
-7.48
FY 2025
EV / Sales
0.00
FY 2025
Price / book
1.90
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-11.88%
FY 2025
FCF yield
-8.07%
FY 2025
Debt / equity
0.00
FY 2025
Current ratio
28.66
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-263K
Operating income
$-119.66M
EBITDA
$-103.43M
Net income
$-103.69M
Diluted EPS
-$1.83
Shares outstanding
56,664,226
Trading
Open
$48.93
Previous close
$48.76
Day range
$47.45 – $50.21
52-week range
$14.79 – $52.39
50-day avg
$42.40
200-day avg
$29.55
Volume
844,241
Avg volume
1,387,413
Beta
0.40
Price history
+141.38% over 1Y
Compare with peers
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Visit websiteCompany info
CEO
Richard A. Fair
IPO date
Mar 12, 2020
Headquarters
Boulder, CO, US
Country
Fundamentals are annual. Figures labeled with their fiscal year.
